Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of Nova Scotia (BNS) vs Novavax Inc (NVAX) Price & Performance

Bank of Nova ScotiaTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Bank of Nova Scotia vs Novavax Inc — how do they compare? Bank of Nova Scotia trades at $89.84 (market cap $108.32B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Bank of Nova Scotia is far larger — about 82.7× Novavax Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

BNSNVAX
Market Cap
$108.32B$1.31B
Sector
FinancialsHealth
52-Week High
$90.29$11.19
52-Week Low
$56.41$6.22
Dividend Yield
3.64%
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of Nova Scotia

Bank of Nova Scotia (BNS) trades at $88.56, down 0.33% on the day. The stock exhibits a bullish technical trend with strong analyst support, evidenced by a 'Buy' consensus from 53% of covering analysts. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.47 surpassing the $1.42 estimate. The company maintains a solid net income margin of 24.86% and recently announced a dividend of $1.14 per share, highlighting its commitment to shareholder returns.

The outlook for BNS is positive, supported by earnings momentum, a diversified banking model, and an attractive dividend. Key risks include exposure to macroeconomic volatility and competitive pressures in the banking sector. The current valuation, with a P/E of 17.1, appears reasonable relative to its profitability and growth prospects.

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

About Bank of Nova Scotia

Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.

Read more on BNS

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX